Ketamine, Esketamine and Depression

In October 2019, the U.S. Food and Drug Administration (FDA) approved esketamine, a substance chemicallyrelated to the party drug ketamine, as a nasal spray to treat depression (Bahr, 2019). The effectiveness of ketamine for depression was first shown in studies in...

The History of Aromatherapy

In recent years, the global aromatherapy market size was valued at $1.07 billion yearly, according to an industry analysis report for 2014 to 2025 published by Grand View Research. This lucrative growth shows no sign of stopping. Rising awareness about the therapeutic...